Company registration number:
12313140
Medellence Limited
Information for filing with the registrar
30 November 2023
Medellence Limited
Contents
Abridged statement of financial position
Notes to the financial statements
Medellence Limited
Abridged statement of financial position
30 November 2023
|
|
|
2023 |
|
|
|
2022 |
|
|
|
|
Note |
£ |
|
£ |
|
£ |
|
£ |
|
|
|
|
|
|
|
|
|
|
Fixed assets |
|
|
|
|
|
|
|
|
|
Investments |
|
5 |
102 |
|
|
|
102 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
|
|
|
|
102 |
|
|
|
102 |
|
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
|
Debtors |
|
|
155,658 |
|
|
|
156,648 |
|
|
Cash at bank and in hand |
|
|
3,417 |
|
|
|
3,417 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
|
|
159,075 |
|
|
|
160,065 |
|
|
Creditors: amounts falling due |
|
|
|
|
|
|
|
|
|
within one year |
|
|
(
928) |
|
|
|
(
928) |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
Net current assets |
|
|
|
|
158,147 |
|
|
|
159,137 |
|
|
|
|
|
_______ |
|
|
|
_______ |
Total assets less current liabilities |
|
|
|
|
158,249 |
|
|
|
159,239 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
_______ |
|
|
|
_______ |
Net assets |
|
|
|
|
158,249 |
|
|
|
159,239 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
|
|
|
|
|
|
|
Capital and reserves |
|
|
|
|
|
|
|
|
|
Called up share capital |
|
|
|
|
100 |
|
|
|
100 |
Profit and loss account |
|
|
|
|
158,149 |
|
|
|
159,139 |
|
|
|
|
|
_______ |
|
|
|
_______ |
Shareholders funds |
|
|
|
|
158,249 |
|
|
|
159,239 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
|
|
|
|
|
|
|
For the year ending 30 November 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
-
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
-
The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the abridged statement of comprehensive income has not been delivered.
All of the members have consented to the preparation of the abridged statement of comprehensive income and the abridged statement of financial position for the current year ending 30 November 2023 in accordance with Section 444(2A) of the Companies Act 2006.
These financial statements were approved by the
board of directors
and authorised for issue on
30 August 2024
, and are signed on behalf of the board by:
Mrs E Markaryan
Director
Company registration number:
12313140
Medellence Limited
Notes to the financial statements
Year ended 30 November 2023
1.
General information
The company is a private company limited by shares, registered in the UK. The address of the registered office is Medellence Limited, 7 Bell Yard, London, England, WC2A 2JR.
2.
Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3.
Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Fixed asset investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses. Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Impairment
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.
4.
Employee numbers
The average number of persons employed by the company during the year amounted to
1
(2022:
1
).
5.
Investments
|
|
|
|
|
|
|
|
|
|
£ |
|
|
|
|
|
|
Cost |
|
|
|
|
|
|
|
At 1 December 2022 and 30 November 2023 |
102 |
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
Impairment |
|
|
|
|
|
|
|
At 1 December 2022 and 30 November 2023 |
- |
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
Carrying amount |
|
|
|
|
|
|
|
At 30 November 2023 |
102 |
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
At 30 November 2022 |
102 |
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investments in group undertakings |
|
|
|
|
|
|
|
Registered office |
Class of share |
Percentage of shares held |
|
|
|
|
|
|
|
Participating interest |
|
|
|
|
|
Enteromed Limited |
|
England |
Ordinary |
100 |
|
|
|
|
|
|
|
Doctor Gut Limited |
|
England |
Ordinary |
100 |
|
|
|
|
|
|
|
|
|
|
|
|
6.
Related party transactions
Mrs E Markaryan
is director and 100% shareholder of the company.At the year end the company owed to £178 (2022 : £178) for expenses paid on its behalf. Medellence Limited
is 100% shareholder of Enteromed Limited. The company received Management fees of Nil (2022 : Nil) during the period. At the year end the company owed £60,951 (2022 : £61,041) from Enteromed Limited. Medellence Limited
is also 100% shareholder of Doctor Gut limited. At the year end the company owed £95,607 (2022 : £95,607) from Doctor Gut limited.
7.
Controlling party
The controlling party is
Mrs E Markaryan
.
8.
Parent-subsidary relationship
The company holds 100% of the equity shares issued by Enteromed Limited. The subsidiary's registered office address is: 85 Great Portland Street,First Floor,London,England,W1W 7LT The company also holds 100% of the equity shares issued by Doctor Gut Limited. The subsidiary's registered office address is: 7 Bell Yard, London,England WC2A 2JR.